PTX 9908
Alternative Names: PTX-9908Latest Information Update: 30 Oct 2021
Price :
$50 *
At a glance
- Originator Pertinax Therapeutics
- Developer Pertinax Therapeutics; TCM Biotech International
- Class Antineoplastics; CXC chemokines; Peptides
- Mechanism of Action CXCR4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cancer; Liver cancer
Most Recent Events
- 04 Feb 2020 Phase-I/II clinical trials in Liver cancer (Inoperable/Unresectable) in Taiwan (IV) (NCT03812874)
- 07 Feb 2019 TCM Biotech International plans a phase I/II trial for Liver cancer (Inoperable/Unresectable) in Taiwan, in August 2019 (NCT03812874)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Cancer in Europe (IV, Infusion)